Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.35 |
| ▸ | JAK1 | P23458 | 5/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | PDE9A | O76083 | 3/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346674 | 0.95 | DAO (0.41) | JAK2JAK1DAOBRD4PDE9A | |
| SCHEMBL8126131 | 0.83 | DAO (0.40) | DAOBRD4ROCK1 | |
| SCHEMBL2172919 | 0.72 | DAO (0.38) | JAK2JAK1DAOBRD4ROCK1 | |
| SCHEMBL10110509 | 0.72 | NOS3 (0.35) | DAOBRD4EZH2 | |
| SCHEMBL17060505 | 0.71 | DAO (0.34) | DAOBRD4EZH2PARP15 | |
| SCHEMBL9284095 | 0.71 | AURKA (0.34) | JAK2DAOBRD4 | |
| SCHEMBL1346299 | 0.69 | IDH1 (0.49) | DAO | |
| SCHEMBL27157561 | 0.69 | DAO (0.36) | JAK2JAK1DAOTYK2JAK3 | |
| SCHEMBL1346010 | 0.68 | GPR84 (0.43) | DAO | |
| SCHEMBL15566612 | 0.65 | BRD9 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063055-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7700607-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2010-04-20 | — | — | US | disclosed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | KIT, CMA1, C3AR1 | JAK2 174/4885JAK1 158/4885DAO 1887/4885 |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | KIT, CMA1, C3AR1 | JAK2 174/4885JAK1 158/4885DAO 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.